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Importance of the Project 
Tuberous Sclerosis (TS) is an autosomal dominant, multisystem disorder that 
affects 1 in 6000 live births. It is characterized by the development of hamartomas 
(benign tumours) in various organs as well as various neurological disorders. TS 
arises due to mutations in the tumour suppressor genes TSC2 and TSC1, which 
encode Tuberin and Hamartin, respectively. Tuberin has been recently shown to 
bind Cyclin B1, a mitotic cyclin, to control progression from G2 to mitosis of the cell 
cycle. My project aims to characterize the cellular timing and localization of the 
Tuberin and Cyclin B1 complex, using the bimolecular fluorescence 
complementation (BiFC) system. Understanding this interaction would allow for a 
greater understanding of the pathology of Tuberous Sclerosis, therefore 
contributing to the development of effective treatments.  
 
Existing State of Knowledge 
Tuberous Sclerosis (TS) is an autosomal dominant, multisystem disorder that 
affects 1 in 6000 live births. It is characterized by the development of hamartomas 
(benign tumours) in various organs including skin, heart, lung, and brain, as well as 
neurologic manifestations such as epilepsy, mental retardation, and autism. TS 
arises due to mutations in the tumour suppressor genes TSC2 and TSC1. Mutations 
in TSC2 are five times more common than mutations in TSC1, and patients with 
mutations in TSC2 appear to be more severely affected. The protein products of 
TSC2 and TSC1, Tuberin and Hamartin respectively, interact to form a heterodimer 
complex, which regulates the cell cycle as well as other cellular processes such as 
growth, and differentiation through the inhibition of mTOR. It is well known that the 
Tuberin-Hamartin complex functions during G1/S to control these cellular 
processes. However, it has recently been shown that Tuberin also functions during 
the G2/M transition. Tuberin binds to Cyclin B1, a mitotic cyclin that partners with 
Cdk1 (Cyclin-dependent kinase 1), to regulate mitotic onset.  
 
Research Question 
What is the timing and localization of the Tuberin-Cyclin B1 interaction, and 
how does this interaction influence progression through the cell cycle? 
 
Methodology 
My research focuses on the construction of a set of bimolecular fluorescence 
complementation (BiFC) vectors using molecular cloning techniques. The BiFC 
vectors contain the gene of the protein to be studied (Tuberin or Cyclin B1) 
conjugated with the amino (N) or carboxi (C) terminus of the yellow fluorescence 
protein (YFP). When Tuberin and Cyclin B1 interact, a yellow fluorescent complex is 
formed. Furthermore, I transfected mammalian HEK293 cells with these vectors and 
analyzed the expression and interaction of Tuberin and Cyclin B1 in real time using 
live cell fluorescence microscopy.  
 
Your Findings  
 I have successfully created a set of mammalian BiFC vectors where the N- or 
C-terminus of the YFP gene is conjugated to either the N- or C-terminus of the 
Tuberin or Cyclin B1 genes. Furthermore, I have tested the expression of these 
vectors in HEK293 cells and visualized the fluorescent complex formation using live 
cell microscopy.  
My results up to now have demonstrated that two of the four Tuberin-Cyclin 
B1 vector combinations produce yellow fluorescence, while the other two 
combinations exhibit no fluorescence. Knowing which combinations fluorescence 
provides information about the 3D conformation of Tuberin, as its crystal structure 
is currently unknown. Knowing which combinations fluoresce also allows us to 
determine which vector combinations are most useful in terms of studying the 
Tuberin-Cyclin B1 complex.  
Moreover, when HEK293 cells are transfected with these two constructs, the 
fluorescent cells arrest in G2 and do not appear to progress to mitosis. This is 
significant because it confirms that the Tuberin-Cyclin B1 complex inhibits mitotic 
onset. Additionally, literature suggests that bimolecular fluorescent complexes are 
irreversible. However, my results suggest that the BiFC Tuberin-Cyclin B1 complex 
is reversible, perhaps dependent upon concentration of transfected DNA.  
Furthermore, immunofluorescence procedures together with the BiFC 
system are being used to better visualize the cellular localization of the interaction 
between Tuberin and Cyclin B1. Preliminary results suggest that Tuberin and Cyclin 
B1 interact in a peri-nuclear fashion during the G2 phase of the cell cycle, before the 
onset of mitosis.  
Finally, the success of using the BiFC system to analyze the Tuberin-Cyclin B1 
interaction suggests that this model would be advantageous in examining other 
factors and pathways involved in the control of cell size and proliferation. The BiFC 
system could be used to deduce the various mechanisms of not only Tuberous 





Tuberous Sclerosis (TS) is an autosomal dominant, multisystem disorder that 
affects 1 in 6000 live births. It is characterized by the development of hamartomas 
(benign tumours) in various organs as well as numerous neurologic manifestations 
such as epilepsy, mental retardation, and autism. TS arises due to mutations in the 
tumour suppressor genes TSC2 and TSC1. Mutations in TSC2 are five times more 
common than mutations in TSC1, and patients with mutations in TSC2 appear to be 
more severely affected. The protein products of TSC2 and TSC1, Tuberin and 
Hamartin respectively, interact to form a heterodimer complex. This complex 
regulates the cell cycle as well as other cellular processes such as growth and 
differentiation through the inhibition of mTOR. It is well known that the Tuberin-
Hamartin complex functions during G1/S to control these cellular processes. 
However, it has recently been shown that Tuberin also functions during the G2/M 
transition. Tuberin binds to Cyclin B1, a mitotic cyclin that partners with Cdk1 
(Cyclin-dependent kinase 1) to regulate mitotic onset. My project aims to 
characterize the cellular timing and localization of the Tuberin-Cyclin B1 
interaction, through the construction of a variety of mammalian expression vectors 
using the bimolecular fluorescence complementation (BiFC) system. This unique 
system employs the use of yellow fluorescence protein (YFP), in which the N- and C-
terminus of this gene are conjugated to either the N- or C-terminus of the Tuberin or 
Cyclin B1 genes.  Through fluorescence microscopy, I have observed in real time two 
of the four vector combinations interacting via the YFP fragments binding one 
another to produce yellow fluorescence. Moreover, these fluorescent cells appear to 
arrest in G2 and do not progress to mitosis, confirming that the Tuberin-Cyclin B1 
complex does in fact inhibit mitotic onset. Furthermore, immunofluorescence 
procedures suggest that Tuberin and Cyclin B1 interact in a peri-nuclear fashion 
prior to the onset of mitosis.  
Finally, the success of using the BiFC system to analyze the Tuberin-Cyclin B1 
interaction will allow for a greater understanding of the pathology of Tuberous 
Sclerosis and other growth related diseases, like cancer, contributing to the 
development of effective treatments for these diseases.  
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